Truist Financial Keeps Their Buy Rating on Sangamo Biosciences (SGMO)
Truist Financial analyst Nicole Germino maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of ...
Truist cuts Sangamo stock target to $5, maintains Buy rating
Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...
Sangamo price target lowered to $5 from $7 at Truist
Truist analyst Nicole Germino lowered the firm’s price target on Sangamo (SGMO) to $5 from $7 and keeps a Buy rating on the shares. The firm ...
pharmaphorum2d
Can Pfizer, Sangamo energise haemophilia A gene therapy?
Pfizer and Sangamo are hoping for a faster trajectory with their experimental treatment. The partners' one-shot giroctocogene fitelparvovec therapy has cleared a phase 3 trial, showing it was ...
Yahoo Finance2d
Forte Biosciences, Inc. (FBRX)
After hours: January 23 at 4:00:26 PM EST Loading Chart for FBRX ...
pharmaphorum3d
Novartis adds gene therapy for blindness with Gyroscope buy
with rivals including Johnson & Johnson's pharma unit Janssen which bought rights to a gene therapy for the condition from Hemera Biosciences last year, and being absorbed into Novartis should ...
bovnews5d
Why Did Sangamo Therapeutics Inc (SGMO) Stock See 9.88% Surge in the Last 90 Days?
Truist has recently raised Sangamo Therapeutics Inc (SGMO) stock to Buy rating, as announced on December 13, 2024, according to Finviz. Earlier, on December 10, 2024, H.C. Wainwright had reiterated ...
Yahoo Finance1d
Sangamo Therapeutics, Inc. (SGMO)
After hours: 7:57:31 pm GMT-5 ...